SCHEMBL30976294

SCHEMBL30976294

Cn1nc(C(=O)O)c2cccnc2c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT2B Q92831 11/20 0.46
KDM4E B2RXH2 1/20 0.45
KDM6B O15054 1/20 0.45
KDM6A O15550 1/20 0.45
TET3 O43151 1/20 0.45
KDM4A O75164 1/20 0.45
KDM4B O94953 1/20 0.45
KDM5C P41229 1/20 0.45
KDM4D Q6B0I6 1/20 0.45
TET2 Q6N021 1/20 0.45
ALKBH5 Q6P6C2 1/20 0.45
TET1 Q8NFU7 1/20 0.45
FTO Q9C0B1 1/20 0.45
EGLN1 Q9GZT9 1/20 0.45
KDM4C Q9H3R0 1/20 0.45
KDM2A Q9Y2K7 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
KDM3A Q9Y4C1 1/20 0.45
ALDH1A1 P00352 4/20 0.45
MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium Ion SCHEMBL30976291 0.85 ALDH1A1 (0.43) KAT2BL3MBTL1ALDH1A1MAPK1POLB
SCHEMBL30976395 0.84 KDM4E (0.51) KAT2BKDM4EL3MBTL1ALDH1A1MAPK1
SCHEMBL4550466 0.80 KDM4C (0.52) KDM4EKDM6BKDM6ATET3KDM4A
SCHEMBL3652058 0.79 ALDH1A1 (0.64) KAT2BL3MBTL1ALDH1A1MAPK1POLB
SCHEMBL30976343 0.78 MEN1 (0.55) KAT2BKDM4EL3MBTL1ALDH1A1MEN1
SCHEMBL31091763 0.76 KAT2B (0.48) KAT2BKDM4EL3MBTL1KAT2A
SCHEMBL17243617 0.76 KDM4C (0.49) KDM4EKDM6BKDM6ATET3KDM4A
SCHEMBL12266002 0.76 KDM4E (0.41) KAT2BKDM4EKDM6BKDM6ATET3
SCHEMBL30976334 0.74 POLB (0.54) L3MBTL1ALDH1A1POLBSMN1; SMN2MEN1
SCHEMBL16549874 0.72 BRD4 (0.49) KAT2BKDM4EKDM4AKDM4CMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260027113-A1 PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE SOLEY THERAPEUTICS INC (US) 2026-01-29 US disclosed
US-12465603-B2 Phthalazinone based modulators for the treatment of disease SOLEY THERAPEUTICS, INC. (US) 2025-11-11 US disclosed
EP-4619387-A1 PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE Soley Therapeutics, Inc. (US) 2025-09-24 EP disclosed
US-20240374589-A1 PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE SOLEY THERAPEUTICS, INC. 2024-11-14 US disclosed
WO-2024108131-A1 PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE SOLEY THERAPEUTICS, INC. (US) 2024-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12465603-B2 Phthalazinone based modulators for the treatment of disease MKI67, BCL2, CCAR2 KAT2B 112/4885KDM4E 1357/4885KDM6B 871/4885
US-20260027113-A1 PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE NCOR1, NOP56, NCOR2 KAT2B 388/4885KDM4E 3319/4885KDM6B 2561/4885
US-20240374589-A1 PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE MKI67, HDAC6, BCL2 KAT2B 263/4885KDM4E 1526/4885KDM6B 1176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.